Mr. Rashid Bux reports

BIOMARK ALIGNS WITH NATIONAL STRATEGY TO SLASH LUNG CANCER MORTALITY WITH NEXT-GEN LIQUID BIOPSY

November is Lung Cancer Awareness Month, and Biomark Diagnostics Inc. is supporting the Canadian Cancer Society's national plan to reduce lung cancer mortality in Canada by 30 per cent over the next decade.

The early detection activities and goals outlined in the 2026-2035 Pan-Canadian Lung Cancer Action Plan are highly aligned with Biomark's corporate mission of leading the world in early-stage cancer detection using metabolomics and artificial intelligence. This co-ordinated national effort recognizes that early detection is fundamental to saving lives and underscores the urgent need to expand access to innovative screening solutions across all Canadian communities.

"At Biomark, we believe that providing equitable, evidence-based access to early lung cancer detection will transform patient outcomes across Canada," said Rashid Bux, chief executive officer and president of Biomark Diagnostics. "Our clinical results demonstrate the power of AI-enabled biomarker testing in identifying more early-stage cancers, even in non-smokers, directly supporting the action plan's commitment to saving lives nationwide. Our technology complements low-dose CT [computed tomography] screening, addresses barriers in underserved and remote regions, and helps ensure that no Canadian is left behind in the fight against lung cancer."

The action plan also notes the need for innovative diagnostic tools and methods, such as blood-based biomarker testing, to improve diagnostic accuracy and increase the likelihood of early-stage diagnosis. Biomark looks forward to collaborating with national partners, provincial health care providers and community organizations to build capacity and make early lung cancer detection accessible, equitable and effective across Canada. Health care providers and organizations interested in partnering to expand access to innovative early detection solutions are encouraged to contact Biomark.

About Biomark Diagnostics Inc.

Biomark Diagnostics is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine-learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Biomark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

We seek Safe Harbor.